Insmed (NASDAQ:INSM) CFO Sells $262,941.61 in Stock

Insmed, Inc. (NASDAQ:INSM) CFO Sara Bonstein sold 1,517 shares of the stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $173.33, for a total transaction of $262,941.61. Following the sale, the chief financial officer directly owned 83,631 shares in the company, valued at approximately $14,495,761.23. This represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sara Bonstein also recently made the following trade(s):

• On Thursday, January 8th, Sara Bonstein sold 1,447 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $252,023.99.
• On Wednesday, January 7th, Sara Bonstein sold 1,678 shares of Insmed stock. The stock was sold at an average price of $175.07, for a total transaction of $293,767.46.

Insmed Price Performance

Shares of Insmed stock traded down $5.73 during midday trading on Thursday, reaching $170.27. The company had a trading volume of 2,588,589 shares, compared to its average volume of 2,142,398. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The company has a market capitalization of $36.31 billion, a price-to-earnings ratio of -27.51 and a beta of 1.08. The stock has a fifty day simple moving average of $190.79 and a 200 day simple moving average of $151.24. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The firm had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.The firm’s quarterly revenue was up 52.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.27) EPS. As a group, equities research analysts forecast that Insmed, Inc. will post -4.56 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Several large investors have recently bought and sold shares of INSM. Royal Bank of Canada boosted its position in shares of Insmed by 33.2% during the first quarter. Royal Bank of Canada now owns 245,262 shares of the biopharmaceutical company’s stock worth $18,710,000 after purchasing an additional 61,190 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Insmed by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 109,489 shares of the biopharmaceutical company’s stock valued at $8,364,000 after buying an additional 4,176 shares in the last quarter. Caxton Associates LLP acquired a new stake in Insmed during the 1st quarter worth $441,000. Woodline Partners LP lifted its holdings in Insmed by 53.3% during the first quarter. Woodline Partners LP now owns 248,770 shares of the biopharmaceutical company’s stock worth $18,979,000 after acquiring an additional 86,540 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Insmed by 10.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 539,484 shares of the biopharmaceutical company’s stock valued at $41,157,000 after acquiring an additional 52,637 shares during the period.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Analyst Ratings Changes

A number of research firms have issued reports on INSM. Evercore ISI restated an “outperform” rating and set a $180.00 target price on shares of Insmed in a research report on Wednesday, October 1st. Cowen set a $241.00 price objective on shares of Insmed in a report on Thursday, December 18th. Rothschild Redb raised shares of Insmed to a “strong-buy” rating in a report on Thursday, December 4th. HC Wainwright dropped their target price on shares of Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, Wells Fargo & Company set a $195.00 price target on Insmed in a research note on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus price target of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.